Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 110 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Review, H1 2016', provides in depth analysis on Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted pipeline therapeutics. 

The report provides comprehensive information on the Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Overview 10
Therapeutics Development 11
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Stage of Development 11
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Therapy Area 12
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Indication 13
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Pipeline Products Glance 15
Late Stage Products 15
Early Stage Products 16
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Companies 17
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Products under Development by Universities/Institutes 22
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Therapeutics Assessment 24
Assessment by Monotherapy/Combination Products 24
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 29
Acetylon Pharmaceuticals, Inc. 29
Chong Kun Dang Pharmaceutical Corp. 31
HitGen LTD 32
Kancera AB 33
Karus Therapeutics Limited 34
Lycera Corp. 35
Merck & Co., Inc. 36
Millennium Pharmaceuticals, Inc. 37
OncoHoldings, Inc. 38
Quimatryx, S.L. 39
Sigma-Tau S.p.A. 40
SK Biopharmaceuticals Co., Ltd. 41
Takeda Pharmaceutical Company Limited 42
TetraLogic Pharmaceuticals 43
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Drug Profiles 44
ACY-241 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ACY-738 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ACY-775 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
C-1A - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
CKD-506 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
CKD-L - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Drugs to Inhibit HDAC6 for Oncology - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
HG-3001 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
IKH-12 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
KA-2507 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
KAN-0439221 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
KAN-439782 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
KAR-3000 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
N-140 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
ONCO-101 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
QTX-100 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
QTX-102 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
QTX-125 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
remetinostat - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
ricolinostat - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Small Molecule to Inhibit HDAC6 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small Molecule to Inhibit HDAC6 for Charcot-Marie-Tooth Disease - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecule to Inhibit HDAC6 for Oncology - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
Small Molecule to Inhibit HDAC6 for Sepsis - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Small Molecules to Inhibit HDAC-6 for Immunology, Oncology and Genetic Disorders - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
Small Molecules to Inhibit HDAC6 for Autoimmune Diseases - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
Small Molecules to Inhibit HDAC6 for Neurodegenerative, Autoimmune and Inflammatory Diseases - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
Small Molecules to Inhibit HDAC6 for Oncology - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Small Molecules to Inhibit HDAC6 for Oncology and Immunology - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
Small Molecules to Inhibit Histone Deacetylase 6 for Oncology - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
ST-3595 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
vorinostat - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Dormant Projects 88
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) - Featured News & Press Releases 90
Jun 03, 2016: Acetylon Collaborators Publish ASCO Abstracts Demonstrating Immunomodulatory Properties of Ricolinostat in Preclinical Melanoma Models 90
Apr 20, 2016: Acetylon Announces the Presentation of Preclinical Data at AACR Supporting the Use of Selective HDAC6 Inhibition to Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 91
Dec 07, 2015: Acetylon Presents Data from Three Phase 1b Studies of Ricolinostat (ACY-1215) for the Treatment of Lymphoma and Multiple Myeloma 92
Dec 07, 2015: Acetylon Presents Data on the use of HDAC 6 Inhibitors Ricolinostat and ACY-241 in Combination with Pomalidomide for the Treatment of Multiple Myeloma 94
Nov 06, 2015: Acetylon's Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-tumor Activity of Paclitaxel in Preclinical Solid Tumor Models 96
Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 98
Jun 15, 2015: Acetylon Pharmaceuticals Presented Positive Preliminary Data from Phase 1b/2 Trial of Ricolinostat in Combination with Pomalyst as Potential Oral Treatment for Patients with Multiple Myeloma 98
Apr 22, 2015: Acetylon Presents Data on Synergistic Activity of Selective HDAC6 Inhibition in Preclinical Models of Multiple Myeloma and Mantle Cell Lymphoma at the American Association for Cancer Research Annual Meeting 99
Jan 21, 2015: Acetylon Presents at the Wells Fargo Celgene Partnership Forum 100
Dec 18, 2014: TetraLogic Announces Initiation of a Randomized Phase 2 Clinical Trial of SHAPE in Subjects With Cutaneous T-Cell Lymphoma 101
Dec 09, 2014: Acetylon Pharmaceuticals Announces Ricolinostat Continues to Demonstrate Clinically Meaningful and Durable Disease Response Rates in Phase 1b Combination Studies in Multiple Myeloma 101
Dec 04, 2014: Acetylon Pharmaceuticals Initiates Phase 2 Study of Ricolinostat (ACY-1215) in Combination with Pomalyst 103
Dec 01, 2014: Acetylon's Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition 103
Jun 13, 2014: Acetylon Pharmaceuticals Reports Ricolinostat (ACY-1215) is Active and Well-tolerated in Ongoing Phase 1b Studies in Patients with Refractory Multiple Myeloma at the 19th Congress of the EHA 107
May 28, 2014: TetraLogic Pharmaceuticals to Present Data From Its Clinical Investigation of SHAPE at the Annual American Society of Clinical Oncology Meeting 108
Appendix 109
Methodology 109
Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110

List of Tables

Number of Products under Development for, H1 2016 11
Number of Products under Development by Therapy Area, H1 2016 12
Number of Products under Development by Indication, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Early Stage Products, H1 2016 16
Number of Products under Development by Companies, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Development by Companies, H1 2016 (Contd..2) 20
Products under Development by Companies, H1 2016 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H1 2016 22
Products under Investigation by Universities/Institutes, H1 2016 23
Assessment by Monotherapy/Combination Products, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 28
Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 29
Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 31
Pipeline by HitGen LTD, H1 2016 32
Pipeline by Kancera AB, H1 2016 33
Pipeline by Karus Therapeutics Limited, H1 2016 34
Pipeline by Lycera Corp., H1 2016 35
Pipeline by Merck & Co., Inc., H1 2016 36
Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 37
Pipeline by OncoHoldings, Inc., H1 2016 38
Pipeline by Quimatryx, S.L., H1 2016 39
Pipeline by Sigma-Tau S.p.A., H1 2016 40
Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 41
Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 42
Pipeline by TetraLogic Pharmaceuticals, H1 2016 43
Dormant Projects, H1 2016 88
Dormant Projects (Contd..1), H1 2016 89